Tag: protocol

LUXEMBOURG, Aug. 10, 2025 (GLOBE NEWSWIRE) -- Bitcoin Swift (BTC3), a decentralized financial operating system integrating programmable PoY (Proof of Yield) rewards, AI-powered smart contracts, decentralized identity, and a hybrid PoW plus PoS consensus, has announced the latest developments in its Stage 4 presale. The presale is currently priced at $4, with a planned launch price of $15, offering Stage 4 participants an APY of 106%.

NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Dyne Therapeutics, Inc. (“Dyne” or the “Company”) (NASDAQ: DYN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

LUXEMBOURG, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Bitcoin Swift (BTC3), a next-generation financial protocol combining AI-powered smart contracts with decentralized identity governance, has officially entered Stage 4 of its presale. The project reports over $580,000 in total contributions, 2,100+ buyers, and an APY of 106% for participants who join before the stage concludes.

London, UK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- August 2025 | Global – In a significant move that’s drawing attention from institutional investors and retail users alike, Xauras, a next-generation decentralized liquidity protocol, has officially launched into the global DeFi lending market—bringing with it a technology-driven, risk-optimized alternative to traditional finance and early DeFi models.

Consumer Search Data Reveals Expanding Curiosity Around Oral Probiotics and Ingredient Transparency in 2025

SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the Rocket Pharmaceuticals class action lawsuit – captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049 (D.N.J.) – seeks to represent purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities and charges Rocket Pharmaceuticals and one of Rocket Pharmaceuticals’ top executives with violations of the Securities Exchange Act of 1934. A subsequently filed case is captioned Yankov v. Rocket Pharmaceuticals, Inc., No. 25-cv-13532 (D.N.J.).

Investors can contact the law firm at no cost to learn more about recovering their losses

NexZen Extracts Expands Indoor-Grown THCA Flower Lineup with 11 New Strains